Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Blood Transfusion Diagnostics Market Share

ID: MRFR//0620-HCR | 200 Pages | Author: Kinjoll Dey| April 2024

The blood transfusion diagnostics industry helps ensure safe and successful transfusions. This ensures patients benefit from blood transfusions. Companies in this field utilize several market share positioning strategies to become industry leaders. This measure is a response to rising worldwide blood product demand.
Companies are now offering a wide variety of blood transfusion diagnostic products. This category includes blood grouping and typing reagents, infectious disease screening assays, and cutting-edge compatibility testing technologies. Diverse product lines allow firms to meet healthcare and blood bank needs. This lets enterprises meet these groups' demands.
New technologies are needed to compete in blood transfusion diagnosis. For faster and more accurate diagnosis, companies are investing in nucleic acid testing (NAT) and automation. Using many technologies may provide one an edge over competitors.
Building good relationships with healthcare institutions and blood banks is crucial to the plan. Close collaboration with these firms may lead to preferred supplier status and long-term contracts, which are financially beneficial. Strategic partnerships like this one also help the organization understand its evolving requirements and connect with key stakeholders for mutual benefit.
Due to the worldwide nature of blood transfusion diagnostics, companies are rapidly expanding into foreign markets. This approach requires building distribution networks, forming alliances, and obtaining regulatory clearances in many sectors. Companies benefit from global presence since it helps them access more customers and establishes them as trusted providers.
Blood protection is crucial, and companies are striving to lead the way in blood filtering technology. Screening test sensitivity and specificity are being improved to reduce blood transfusion-transmitted illnesses. This research and development aims to improve screening assays. A company's image as a reliable supplier improves when it prioritizes safety.
Because blood transfusion tests are so important, regulatory compliance is crucial. Company obligation is to comply with strict regulatory requirements set by health authorities worldwide. This ensures that their goods are high-quality and safe and helps them acquire the confidence of healthcare professionals and regulatory bodies, making it easier to extend their market share.
Companies are supporting blood transfusion training programs for medical personnel. This includes instructional materials, workshop organization, and training sessions. Companies may increase product efficiency by providing end-users with information, which boosts customer happiness and loyalty.
Businesses are developing cost-effective and expanding nation-specific solutions. Various economic conditions are being considered. This approach offers economical, high-quality diagnostics to suit healthcare system requirements in low-income settings. We do this to meet system needs. Penetration of these markets is crucial to expanding market share.
Excellent customer service is crucial to market positioning. More organizations are investing in efficient customer service staff, technical support, and fast-response technologies. Fast assistance and problem-solving help meet client demands. These factors help businesses build long-term collaborations and establish themselves as credible blood transfusion diagnostics partners.

Blood Transfusion Diagnostics Market Overview 


The Blood Transfusion Diagnostics Market is expected to reach USD 3915.8 Million by 2030 at 6.7% CAGR during the forecast period 2022-2030. Blood transfusion diagnostics is the intravenous transfer of blood or blood products. Blood transfusions can be used to replace blood components that have been lost. The most common blood components transfused include red blood cells, white blood cells, platelets, clotting factors, and plasma. During an emergency or a serious case of massive blood loss, these blood components are crucial to laboratories and hospitals. When hemoglobin levels fall below 100g/L, RBC transfusion is required. Before being transfused, blood from a donor must be checked for a variety of infectious diseases. Blood transfusion demand is being driven by the rising prevalence of chronic and infectious diseases such as severe anemia, cancer, hemophilia, kidney disease, liver disease, severe infection, sickle cell disease, and thrombocytopenia, as well as the introduction of technologically advanced products. As a result, blood transfusion diagnostics play a vital role in preventing infection in both the recipient and the healthcare workers. The expansion of this market is fueled by rising infectious disease prevalence, an increase in the number of blood transfusion procedures, the need for screened blood products, and increased campaigning or awareness campaigns. The demand for blood and blood products outnumbers the supply, adding to the Blood Transfusion Diagnostics market's expansion.
 

Blood Transfusion Diagnostics Market


Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.



  • To provide detailed analysis of the market structure along with forecast for the next seven years of the various segments and sub-segments of the Blood Transfusion Diagnostics market.

  • To provide insights about factors affecting the market growth.

  • To analyze the Blood Transfusion Diagnostics market based on various factors- Price Analysis, Supply Chain Analysis, Porters’ Five Force Analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies - Americas, Europe, Asia Pacific and Middle East & Africa and their countries.

  • To provide country level analysis of the market with respect to the current market size and future prospective.

  • To provide country level analysis of the market for segments by product, by technology, by end and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the Blood Transfusion Diagnostics Market.

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Blood Transfusion Diagnostics market.



Key Players


Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S),  Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics (U.S), Beckman Coulter (U.S), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany),  DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).


The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions



Blood Transfusion Diagnostics Market Segmentation


Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.


Blood Transfusion Diagnostics Market Regional Analysis


Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.


Recent Development 


Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.


Intended Audience



  • Medical device manufactures

  • Medical devices suppliers

  • Contract Research Organizations (CROs)

  • Research and Development (R&D) Companies

  • Academic Medical Institutes and Universities


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.